An interventional study of Temperature-sensitive hydroxybutyl chitosan-loaded concentrated growth factor and Temperature-sensitive hydroxybutyl chitosan in Alveolar Bone Loss, Alveolar Ridge Resorption After Extraction and Tooth, Impacted, sponsored by Stomatological Hospital Affiliated with Fujian Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-08-21.
Sponsored by Stomatological Hospital Affiliated with Fujian Medical University · Not applicable, Interventional, and Treatment
This study aims to combine real-world research with relevant bone repair materials and techniques to improve alveolar bone resorption in extraction sockets following impacted wisdom tooth removal, while achieving effective bone preservation or promoting bone regeneration. All eligible cases within specified parameters will be included in the clinical study scope. Based on real-world clinical data, we will proactively collect postoperative clinical examination findings and imaging data. Statistical analysis will be performed on clinical outcomes and follow-up data from patients undergoing mandibular impacted M3 extraction. The study aims to clarify the therapeutic efficacy of the thermosensitive hydroxyethylchitosan-loaded concentrated growth factor group in repairing mesial bone defects of M2s following M3 extraction.
This study is a prospective observational investigation conducted in a real-world clinical setting. Its objective is to systematically evaluate the clinical efficacy and bone regeneration capacity of a novel composite material, thermosensitive hydroxybutyl chitosan (THBC) loaded with concentrated growth factor (CGF), in the clinical efficacy and bone regenerative capacity for restoring mesial bone defects in second molars following mandibular impacted third molar extraction. The study will enroll patients requiring extraction of mandibular mesial or lower impacted third molars. All participants will select different bone repair options based on clinical circumstances and personal preference, including the THBC+CGF experimental group, autogenous bone graft group, THBC group, CGF group, collagen sponge group, and unfilled control group. Baseline data and intraoperative details will be comprehensively described.
318 studies on the registry are indexed under Alveolar Bone Loss; 79 are open to participants now.
This study's planned enrollment of 136 is above the median of 25 across 269 interventional studies indexed under Alveolar Bone Loss.
Browse Alveolar Bone Loss studies →Stomatological Hospital Affiliated with Fujian Medical University is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Following extraction of the patient's mandibular third molar, immediate placement of a THBC/CGF composite filling was performed. Autologous venous blood was centrifuged, and the resulting CGF clot was compressed into a CGF membrane using specialised instruments. This membrane was mixed with 0.5 mL of THBC solution and injected into the extraction socket. The mixture gelled at 37 degrees Celsius, with a gelation time of less than or equal to 1 minute. Routine infection prevention measures were implemented postoperatively.
Combination Product: Temperature-sensitive hydroxybutyl chitosan-loaded concentrated growth factor
Following extraction of the patient's mandibular third molar, 0.5 mL of THBC was injected into the extraction socket and allowed to gel at 37 degrees Celsius (gelation time less than or equal to 1 minute). Routine infection prevention measures were implemented postoperatively.
Device: Temperature-sensitive hydroxybutyl chitosan
Immediately prior to surgery, venous blood is drawn from the patient and centrifuged without delay. Upon completion of preparation, the resulting CGF clot is compressed into a CGF membrane using specialised instruments. This CGF membrane is implanted directly into the extraction socket within 30 minutes of preparation to cover the bone defect area.Routine infection prevention measures were implemented postoperatively.
Biological: Autologous Concentrated Growth Factor
Natural healing after tooth extraction: The extraction socket is filled solely by a blood clot without any implanted biomaterials. Routine infection prevention measures were implemented postoperatively.
Other: Natural Healing without Biomaterial Intervention
* THBC Component: Its key component is hydroxybutyl chitosan. The product is supplied as a clear or light yellow, easily flowing liquid at storage temperature (2-8 degrees Celsius) and undergoes a sol-gel transition to form a transparent or semi-transparent gel at body temperature (37 +/- 2 degrees Celsius). The product is composed of hydroxybutyl chitosan, glycerol, and purified water. It is designed to provide a physical barrier, create a moist wound-healing environment, and alleviate pain. * CGF Component: Concentrated Growth Factor (CGF) is a third-generation autologous platelet concentrate obtained from the patient's own venous blood through a specific centrifugation process. It presents as a dense, three-dimensional fibrin matrix rich in platelets, leukocytes, cytokines, and growth factors (such as PDGF, TGF-beta, VEGF). * Composite Process: Mixed under sterile conditions, injection flow rate less than or equal to 0.5 mL/s.
Its key component is hydroxybutyl chitosan. The product is supplied as a clear or light yellow, easily flowing liquid at storage temperature (2-8 degrees Celsius) and undergoes a sol-gel transition to form a transparent or semi-transparent gel at body temperature (37 +/- 2 degrees Celsius). The product is composed of hydroxybutyl chitosan, glycerol, and purified water. It is designed to provide a physical barrier, create a moist wound-healing environment, and alleviate pain.
Concentrated Growth Factor (CGF) is a third-generation autologous platelet concentrate obtained from the patient's own venous blood through a specific centrifugation process. It presents as a dense, three-dimensional fibrin matrix rich in platelets, leukocytes, cytokines, and growth factors (such as PDGF, TGF-beta, VEGF).
After tooth extraction, gently scraping the bone wall induces bleeding, allowing a natural blood clot to form. Within 30 minutes postoperatively, ensure the clot fills more than 90 percent of the socket without applying experimental biomaterials.
7-day postoperative healing score
Healing of the extraction wound and granulation tissue formation assessed at 7 days postoperatively. Scoring: 3 = complete healing (no gingival redness or swelling); 2 = fistula detected at the distal-middle area of the second molar or mild gingival redness/swelling without infection; 1 = poor healing or obvious redness/swelling without pus; 0 = presence of pus (infection).
Time frame: 7 days after surgery
Alveolar Bone Width（ Millimeters）
Width of the alveolar bone measured as the distance from the crest of the buccal alveolar ridge to the crest of the lingual alveolar ridge, using the CT scanner's built-in measurement software.
Time frame: Pre-operative, 3 months post-operative，6 months post-operative
Alveolar Bone Height（Millimeters）
Height of the alveolar bone measured as the vertical distance from the highest point of the alveolar bone to the upper wall of the mandibular canal, using the CT scanner's built-in measurement software.
Time frame: Pre-operative; 3 months post-operative，6 months post-operative
Second Molar Mobility (Modified Miller Grade)
Mobility of the second molar assessed using the modified Miller grading system with two standard metal dental instrument handles (e.g., mouth mirror handle and probe handle). Grade 0 = no mobility; Grade I = labial/lingual mobility \<1 mm; Grade II = labial/lingual mobility 1-2 mm; Grade III = labial/lingual mobility \>2 mm with vertical mobility.
Time frame: Preoperative，7 days after surgery, 14 days after surgery, 3 months after surgery
Mouth Opening Width（Millimeters）
Maximum interincisal distance (between the incisal margins of the upper and lower incisors) measured using standard calipers.
Time frame: Preoperative，1 day after surgery, 3 days after surgery, 7 days after surgery
Postoperative pain (VAS score)
Patient-reported pain intensity on a 10-point visual analogue scale (VAS) with verbal descriptors: 0 = no pain; 1-3 = mild pain, not interfering with sleep; 4-6 = moderate pain, mildly interfering with sleep; 7-9 = severe pain, preventing sleep and requiring medication; 10 = worst possible pain.
Time frame: 1 day after surgery, 3 days after surgery, 7 days after surgery, 14 days after surgery
Swelling degree（millimeter）
Facial swelling measured as the distance from the tragus to the corner of the mouth on the extraction side, using a soft tape measure.
Time frame: Preoperative, 1 day postoperative, 3 days postoperative, 7 days postoperative
Second Molar Probing Depth (Mean of Three Sites)
Probing depth (PD) recorded at three sites of the second molar periodontium (buccal distal-medial, mid-distal, and lingual distal-medial) using a periodontal probe. The final reported value will be the mean of the three site measurements. PD is defined as the distance from the free gingival margin to the bottom of the periodontal pocket.
Time frame: Preoperative, 14 days postoperative, 3 months postoperative
Second Molar Probing Tenderness（Ordinal category ）
Vertical percussion of the occlusal surface of the second molar (M2) using the handle of a metal dental mirror, compared with the contralateral healthy tooth. Response graded as: (-) = no discomfort, identical to control; (±) = abnormal sensation/soreness, not clearly pain; (+) = clear pain, tolerable; (++) = sharp pain provoking avoidance; (+++) = severe pain, refusal of further examination.
Time frame: Preoperative，7 days after surgery, 14 days after surgery, 3 months after surgery
Postoperative Bleeding
Presence of active bleeding from the extraction wound and presence of blood clot formation assessed at 30 minutes postoperatively. Recorded as present/absent.
Time frame: 30 minutes after surgery
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stomatological Hospital Affiliated with Fujian Medical University